Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Accenture
QuintilesIMS
McKinsey
Julphar
Harvard Business School
UBS
Fuji
AstraZeneca

Generated: August 20, 2018

DrugPatentWatch Database Preview

GILEAD Company Profile

« Back to Dashboard

Summary for GILEAD

Drugs and US Patents for GILEAD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead TRUVADA emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 021752-001 Aug 2, 2004 AB RX Yes Yes 8,592,397 ➤ Sign Up Y ➤ Sign Up
Gilead Sciences Inc VIREAD tenofovir disoproxil fumarate POWDER;ORAL 022577-001 Jan 18, 2012 RX Yes Yes 5,935,946*PED ➤ Sign Up ➤ Sign Up
Gilead Sciences Inc STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100-001 Aug 27, 2012 RX Yes Yes 7,635,704 ➤ Sign Up Y Y ➤ Sign Up
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251-001 Feb 7, 2018 RX Yes Yes 7,390,791 ➤ Sign Up Y Y ➤ Sign Up
Gilead Sciences Inc VIREAD tenofovir disoproxil fumarate POWDER;ORAL 022577-001 Jan 18, 2012 RX Yes Yes 6,043,230*PED ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for GILEAD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead Sciences Inc VIREAD tenofovir disoproxil fumarate TABLET;ORAL 021356-001 Oct 26, 2001 6,043,230*PED ➤ Sign Up
Gilead Sciences Inc VIREAD tenofovir disoproxil fumarate TABLET;ORAL 021356-002 Jan 18, 2012 5,922,695*PED ➤ Sign Up
Gilead Sciences Inc STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100-001 Aug 27, 2012 5,922,695*PED ➤ Sign Up
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-002 Jun 15, 2007 7,109,205 ➤ Sign Up
Gilead Sciences Inc STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100-001 Aug 27, 2012 6,043,230*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GILEAD drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 200 mg ➤ Subscribe 2012-07-16
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2015-02-09
➤ Subscribe Tablets 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg ➤ Subscribe 2017-05-19
➤ Subscribe Tablets 300 mg ➤ Subscribe 2010-01-26
➤ Subscribe Tablets 200 mg/25 mg/300 mg ➤ Subscribe 2015-05-20
➤ Subscribe Tablets 10 mg ➤ Subscribe 2010-06-08
➤ Subscribe Tablets 200 mg/300 mg ➤ Subscribe 2008-09-26
➤ Subscribe Tablets 600 mg/200 mg/300 mg ➤ Subscribe 2008-12-29
➤ Subscribe Tablets 150 mg, 200 mg, and 250 mg ➤ Subscribe 2012-05-17
➤ Subscribe Tablets 150 mg ➤ Subscribe 2015-12-09

Non-Orange Book US Patents for GILEAD

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,197,958 Carboxylic acid derivatives, their preparation and use ➤ Sign Up
5,914,400 Method and compositions for the synthesis of BCH-189 and related compounds ➤ Sign Up
9,533,000 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
9,580,392 HIV replication inhibiting pyrimidines ➤ Sign Up
6,346,627 Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for GILEAD Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0140035 00135 Estonia ➤ Sign Up PRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014
2015 00055 Denmark ➤ Sign Up PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER EN TERAPEUTISK AEKVIVALENT FORM DERAF, SOM ER BESKYTTET AF GRUNDPATENTET, SASOM ET FARMECEUTISK ACCEPTABELT SALT AF RILPIVIRIN, HERUNDER HYDROCHLORIDSALTET AF RILPIVIRIN, TENOFOVIR, NAVNLIG TENOFOVIRDISOPROXILFUMARAT; REG. NO/DATE: EU/1/11/737/001-002 20111128
0170009 00226 Estonia ➤ Sign Up PRODUCT NAME: IDELALISIIB;REG NO/DATE: EU/1/14/938 19.09.2014
2017 00007 Denmark ➤ Sign Up PRODUCT NAME: IDELALISIB; REG. NO/DATE: EU/1/14/938 20140924
C0034 France ➤ Sign Up PRODUCT NAME: ADEFOVIR DIPIVOXIL; REGISTRATION NO/DATE: EU/1/03/251/001 20030306
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Mallinckrodt
Chinese Patent Office
Baxter
UBS
Argus Health
Express Scripts
Farmers Insurance
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.